Dotarem Helps Detect Brain, Spine Problems

Friday, 22 Mar 2013 02:10 PM

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
Dotarem (gadoterate meglumine) has been approved by the FDA as a contrast agent for use in MRIs of the brain, spine, and other parts of the central nervous system.
The imaging agent helps radiologists detect lesions and other abnormalities. Dotarem and similar agents all carry a boxed label warning of the risk of nephrogenic systemic fibrosis, a rare yet dangerous condition that can develop in people with kidney disease, the FDA said.
The condition is characterized by pain and thickening of the skin.
Dotarem's safety and effectiveness were evaluated in clinical studies involving 245 adults and 38 children with suspected abnormalities of the central nervous system. All side effects were rare, but the most common ones included nausea, headache, a burning sensation, and injection-site pain and coldness.
Dotarem is marketed by Guerbet LLC, based in Bloomington, Ind.

© 2014 NewsmaxHealth. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Immune Drug Fights Skin Cancer

Monday, 22 Dec 2014 16:07 PM

TheU.S. Food and Drug Administration approved Bristol-Myers Squibb's skin cancer drug, more than three months before the . . .

First New Flu Treatment in 15 Years

Monday, 22 Dec 2014 08:19 AM

The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals' intravenous flu drug, sending the company's sha . . .

Drug Fights Antibiotic-Resistant Infection

Saturday, 20 Dec 2014 10:33 AM

Cubist Pharmaceutical drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved